Skip to main content
. 2018 Jun 20;245(4):387–398. doi: 10.1002/path.5079

Figure 4.

PATH-5079-FIG-0004-c

Predicted miR‐1179 targets in NSCLC cells and in NSCLC patients. (A) Expression of the predicted miR‐1179 targets CCNE1, NUAK2 and SPOCK1 was measured in miR‐1179 mimic‐transfected NCI‐H1993 and NCI‐H2073 cells. Fold changes relative to control cells are shown. *p < 0.05. (B) Stably transfected A549pCMV‐miR‐1179 cells were treated with an miR‐1179 inhibitor, and RT‐PCR showed upregulated expression of CCNE1, NUAK2 and SPOCK1. *p < 0.05. (C) Western blot analysis of cyclin E1 in NCI‐H1993 and NCI‐H2073 cells transfected with control RNA (–) or miR‐1179 (+). (D) Luciferase activity in cells that were cotransfected with a luciferase reporter construct containing either the wild‐type (WT) or the mutated (MUT) 3′‐UTR of CCNE1 and with miR‐1179 mimics. RLU, relative luminescence units.